Emerging Therapeutic Targets for Male Germ Cell Tumors.

about

The roles of the PD-1/PD-L1 pathway at immunologically privileged sites.L1-CAM is commonly expressed in testicular germ cell tumours.

P2860

Q39354025-9E7F5C49-8FFD-40F5-8728-B037EA006805 Q53159544-6798116D-4EE7-4B61-A3E4-8DF3DCF1D701

P2860

Emerging Therapeutic Targets for Male Germ Cell Tumors.

Item

http://www.wikidata.org/entity/Q38602699

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Emerging Therapeutic Targets for Male Germ Cell Tumors.

@en

type

Item

label

Emerging Therapeutic Targets for Male Germ Cell Tumors.

@en

prefLabel

Emerging Therapeutic Targets for Male Germ Cell Tumors.

@en

P1476

Emerging Therapeutic Targets for Male Germ Cell Tumors.

@en

P2093

Christian Daniel Fankhauser

http://www.w3.org/2001/XMLSchema#string

Friedemann Honecker

http://www.w3.org/2001/XMLSchema#string

Peter Karl Bode

http://www.w3.org/2001/XMLSchema#string

P2860

Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors

Cancer statistics, 2015

PD-1 and its ligands in tolerance and immunity

Epidermal growth factor-related peptides and their receptors in human malignancies

Long-term survival in patients with germ cell testicular cancer: a population-based competing-risks regression analysis.

A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors.

Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors.

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation.

Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial

P2888

s11912-015-0479-4

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11912-015-0479-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jörg Beyer

P577

2015-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1050157713

http://www.w3.org/2001/XMLSchema#string

P698

26449842

http://www.w3.org/2001/XMLSchema#string

Emerging Therapeutic Targets for Male Germ Cell Tumors.

about

P2860

P2860

Emerging Therapeutic Targets for Male Germ Cell Tumors.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698